{"pmid":32362977,"pmcid":"PMC7188381","title":"Abnormal Hemostatic Parameters and Risk of Thromboembolism Among Patients With COVID-19 Infection.","text":["Abnormal Hemostatic Parameters and Risk of Thromboembolism Among Patients With COVID-19 Infection.","J Hematol","Castelli, Roberto","Gidaro, Antonio","32362977"],"journal":"J Hematol","authors":["Castelli, Roberto","Gidaro, Antonio"],"date":"2020-05-05T11:00:00Z","year":2020,"_id":"32362977","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.14740/jh636","topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138495982239745,"score":9.490897,"similar":[{"pmid":32396963,"title":"SARS-2 Coronavirus-Associated Hemostatic Lung Abnormality in COVID-19: Is It Pulmonary Thrombosis or Pulmonary Embolism?","text":["SARS-2 Coronavirus-Associated Hemostatic Lung Abnormality in COVID-19: Is It Pulmonary Thrombosis or Pulmonary Embolism?","Semin Thromb Hemost","Thachil, Jecko","Srivastava, Alok","32396963"],"journal":"Semin Thromb Hemost","authors":["Thachil, Jecko","Srivastava, Alok"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32396963","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1055/s-0040-1712155","topics":["Mechanism","Diagnosis","Treatment"],"weight":1,"_version_":1666627827801260033,"score":57.674675},{"pmid":32456506,"title":"Hemostatic laboratory derangements in COVID-19 with a focus on platelet count.","text":["Hemostatic laboratory derangements in COVID-19 with a focus on platelet count.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus disease in 2019 (COVID-19) which rapidly evolved from an outbreak in Wuhan, China into a pandemic that has resulted in over millions of infections and over hundreds of thousands of mortalities worldwide. Various coagulopathies have been reported in association with COVID-19, including disseminated intravascular coagulation (DIC), sepsis-induced coagulopathy (SIC), local microthrombi, venous thromboembolism (VTE), arterial thrombotic complications, and thrombo-inflammation. There is a plethora of publications and conflicting data on hematological and hemostatic derangements in COVID-19 with some data suggesting the link to disease progress, severity and/or mortality. There is also growing evidence of potentially useful clinical biomarkers to predict COVID-19 progression and disease outcomes. Of those, a link between thrombocytopenia and COVID-19 severity or mortality was suggested. In this opinion report, we examine the published evidence of hematological and hemostatic laboratory derangements in COVID-19 and the interrelated SARS-CoV-2 induced inflammation, with a focussed discussion on platelet count alterations. We explore whether thrombocytopenia could be a potential disease biomarker and we provide recommendations for future studies in this regard.","Platelets","Amgalan, Ariunzaya","Othman, Maha","32456506"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus disease in 2019 (COVID-19) which rapidly evolved from an outbreak in Wuhan, China into a pandemic that has resulted in over millions of infections and over hundreds of thousands of mortalities worldwide. Various coagulopathies have been reported in association with COVID-19, including disseminated intravascular coagulation (DIC), sepsis-induced coagulopathy (SIC), local microthrombi, venous thromboembolism (VTE), arterial thrombotic complications, and thrombo-inflammation. There is a plethora of publications and conflicting data on hematological and hemostatic derangements in COVID-19 with some data suggesting the link to disease progress, severity and/or mortality. There is also growing evidence of potentially useful clinical biomarkers to predict COVID-19 progression and disease outcomes. Of those, a link between thrombocytopenia and COVID-19 severity or mortality was suggested. In this opinion report, we examine the published evidence of hematological and hemostatic laboratory derangements in COVID-19 and the interrelated SARS-CoV-2 induced inflammation, with a focussed discussion on platelet count alterations. We explore whether thrombocytopenia could be a potential disease biomarker and we provide recommendations for future studies in this regard."],"journal":"Platelets","authors":["Amgalan, Ariunzaya","Othman, Maha"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32456506","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1080/09537104.2020.1768523","keywords":["covid","sars-cov-2","platelets","thrombocytopenia","thromboinflammation"],"locations":["Wuhan","China","thrombocytopenia","thrombocytopenia"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1668141322605690881,"score":46.647263},{"pmid":32291954,"title":"Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.","text":["Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.","J Thromb Haemost","Arachchillage, Deepa R J","Laffan, Mike","32291954"],"journal":"J Thromb Haemost","authors":["Arachchillage, Deepa R J","Laffan, Mike"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32291954","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jth.14820","topics":["Diagnosis"],"weight":1,"_version_":1666138494330732544,"score":43.77951},{"pmid":32459663,"title":"COVID-19, microangiopathy, hemostatic activation, and complement.","text":["COVID-19, microangiopathy, hemostatic activation, and complement.","In COVID-19, complement activation may contribute to hemostatic activation leading to pathological features such as microvascular injury and coagulopathy.","J Clin Invest","Song, Wen-Chao","FitzGerald, Garret A","32459663"],"abstract":["In COVID-19, complement activation may contribute to hemostatic activation leading to pathological features such as microvascular injury and coagulopathy."],"journal":"J Clin Invest","authors":["Song, Wen-Chao","FitzGerald, Garret A"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32459663","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1172/JCI140183","topics":["Mechanism","Treatment"],"weight":1,"_version_":1667967698973229057,"score":42.351196},{"pmid":32417304,"title":"The need to manage the risk of thromboembolism in COVID-19 patients.","text":["The need to manage the risk of thromboembolism in COVID-19 patients.","COVID-19 first presented in Wuhan, Hubei Province, China, in December 2019. Thought to be of zoonotic origin, it has been named SARS-CoV-2 (COVID-19) and has spread rapidly. As of April 20(th), 2020, there have been more than 2.4 million cases recorded worldwide. The inflammatory process, cytokine storm, and lung injury that are associated with COVID-19 can put patients at an increased risk of thrombosis. It is uncertain what the total incidences of thrombotic events in COVID-19 patients is currently at. Those with more severe disease and with other risk factors, including increasing age, male sex, obesity, cancer, comorbidities, and intensive care unit admission, are at higher risk of these events. However, there is little international guidance on managing these risks in COVID-19 patients. In this paper, we explore the current evidence and theories surrounding thrombosis in these unique patients and reflect on experience from our center.","J Vasc Surg","Khan, Inayat Hussain","Savarimuthu, Sugeevan","Tsun Leung, Marco Shiu","Harky, Amer","32417304"],"abstract":["COVID-19 first presented in Wuhan, Hubei Province, China, in December 2019. Thought to be of zoonotic origin, it has been named SARS-CoV-2 (COVID-19) and has spread rapidly. As of April 20(th), 2020, there have been more than 2.4 million cases recorded worldwide. The inflammatory process, cytokine storm, and lung injury that are associated with COVID-19 can put patients at an increased risk of thrombosis. It is uncertain what the total incidences of thrombotic events in COVID-19 patients is currently at. Those with more severe disease and with other risk factors, including increasing age, male sex, obesity, cancer, comorbidities, and intensive care unit admission, are at higher risk of these events. However, there is little international guidance on managing these risks in COVID-19 patients. In this paper, we explore the current evidence and theories surrounding thrombosis in these unique patients and reflect on experience from our center."],"journal":"J Vasc Surg","authors":["Khan, Inayat Hussain","Savarimuthu, Sugeevan","Tsun Leung, Marco Shiu","Harky, Amer"],"date":"2020-05-18T11:00:00Z","year":2020,"_id":"32417304","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.jvs.2020.05.015","keywords":["anti-coagulation","covid-19","d-dimer","thrombosis","venous thromboembolism"],"locations":["Wuhan","Hubei","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1667058206761811969,"score":41.03019}]}